STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
407
13F, latest reported quarter
What the filings say about RJF
Insiders, 180 days
-$4.1M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-04-07
Planned sales (Form 144), 90 days
$1.3M
1 notice
Raymond James Financial insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, RAYMOND JAMES FINANCIAL INC insiders sold a net $4.1M of stock across 49 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 13, 2024.
The trade is 22.2% of the 45,114 shares held after it.
1 other insider sold within 30 days.
407 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, PCG Elwyn Tashtego S sold about $1.8M of RJF on Jul 28, 2026; 1 other insider sold within 30 days and 407 funds added in the latest 13F quarter.
8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Dec 2, 2024.
The trade is 13.4% of the 43,046 shares held after it.
1 other insider sold within 30 days.
407 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chair RJBank Raney Steven M sold about $998.0K of RJF on Jul 27, 2026; 1 other insider sold within 30 days and 407 funds added in the latest 13F quarter.
Nobody has filed for crossing 5%. That is a fact, not missing data.
RJF planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Allaire Bella Loykhter
Filed 2026-08-28
$1.3M
Elwyn Tashtego S
Filed 2026-07-28
$1.8M
Raney Steven M
Filed 2026-07-27
$998.0K
RJF mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Congress Mid Cap Growth Fund
$25.7M position · as of 2026-07-31
6.8%
CapForce IBD Breakout Opportunities ETF
$671.4K position · as of 2026-07-31
4.1%
Victory Pioneer Mid Cap Value Fund
$22.4M position · as of 2026-07-31
2.9%
iShares U.S. Broker-Dealers & Securities Exchanges ETF
$33.6M position · as of 2026-06-30
2.5%
Select Brokerage and Investment Management Portfolio
$23.6M position · as of 2026-05-31
2.5%
Victory Pioneer Mid Cap Value VCT Portfolio
$2.8M position · as of 2026-06-30
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Paul M. Shoukry
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$23.1M
$34.1M
$6.4M
+167%
+113%
2023
$34.9M
$39.8M
$8.4M
+116%
+54%
2022
$17.6M
$24.8M
$6.1M
+109%
+45%
2021
$13.7M
$33.8M
$4.9M
+93%
+65%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.1M sold by insiders over 180 days, 407 funds added last quarter, $1.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$17.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RJF
FY Sep 2025
$15.9B
FY Sep 2024
$14.9B
FY Sep 2023
$13.0B
FY Sep 2022
$11.3B
FY Sep 2021
$9.9B
Jun 2026
$4.4B
Mar 2026
$4.3B
Dec 2025
$4.2B
Sep 2025
$4.2B
Jun 2025
$3.8B
Mar 2025
$3.8B
Dec 2024
$4.0B
Sep 2024
$4.0B
At each fiscal year end
Single quarter
Net margin, TTM
+13.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RJF
FY Sep 2025
+13.4%
FY Sep 2024
+13.9%
FY Sep 2023
+13.4%
FY Sep 2022
+13.3%
FY Sep 2021
+14.2%
Jun 2026
+13.6%
Mar 2026
+12.8%
Dec 2025
+13.5%
Sep 2025
+14.4%
Jun 2025
+11.3%
Mar 2025
+12.9%
Dec 2024
+14.9%
Sep 2024
+15.0%
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.4B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RJF
FY Sep 2025
$2.2B
FY Sep 2024
$1.9B
FY Sep 2023
-$3.7B
FY Sep 2022
-$19.0M
FY Sep 2021
$6.6B
Jun 2026
-$308.0M
Mar 2026
$1.1B
Dec 2025
-$56.0M
Sep 2025
$752.0M
Jun 2025
$634.0M
Mar 2025
$71.0M
Dec 2024
$789.0M
Sep 2024
$460.0M
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2022-12-31 (42 months older than the period end); equity 2026-06-30
Debt to equity RJF
FY Sep 2025
0.00x
FY Sep 2024
0.00x
FY Sep 2023
0.00x
FY Sep 2022
0.00x
FY Sep 2021
0.00x
Jun 2026
0.00x
Mar 2026
0.00x
Dec 2025
0.00x
Sep 2025
0.00x
Jun 2025
0.00x
Mar 2025
0.00x
Dec 2024
0.00x
Sep 2024
0.00x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt RJF
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Sep 2023
n/a
FY Sep 2022
72.00x
FY Sep 2021
830.88x
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+18.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RJF
FY Sep 2025
+17.7%
FY Sep 2024
+18.9%
FY Sep 2023
+17.7%
FY Sep 2022
+17.0%
FY Sep 2021
+18.3%
Jun 2026
+18.5%
Mar 2026
+17.3%
Dec 2025
+17.1%
Sep 2025
+17.7%
Jun 2025
+18.2%
Mar 2025
+18.9%
Dec 2024
+19.1%
Sep 2024
+18.9%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RJF
FY Sep 2025
+2.5%
FY Sep 2024
+2.6%
FY Sep 2023
+2.2%
FY Sep 2022
+2.1%
FY Sep 2021
+2.6%
Jun 2026
+2.6%
Mar 2026
+2.5%
Dec 2025
+2.5%
Sep 2025
+2.5%
Jun 2025
+2.6%
Mar 2025
+2.7%
Dec 2024
+2.7%
Sep 2024
+2.6%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital RJF
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Sep 2023
n/a
FY Sep 2022
n/a
FY Sep 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed RJF
FY Sep 2025
n/a
FY Sep 2024
n/a
FY Sep 2023
n/a
FY Sep 2022
n/a
FY Sep 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
13.78x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing RJF
FY Sep 2025
16.77x
FY Sep 2024
12.62x
FY Sep 2023
12.62x
FY Sep 2022
14.14x
FY Sep 2021
13.92x
Jun 2026
13.25x
Mar 2026
13.69x
Dec 2025
15.71x
Sep 2025
16.77x
Jun 2025
15.05x
Mar 2025
13.38x
Dec 2024
15.17x
Sep 2024
12.62x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$20.4B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
Enterprise value RJF
FY Sep 2025
$23.0B
FY Sep 2024
$14.2B
FY Sep 2023
$11.7B
FY Sep 2022
$15.2B
FY Sep 2021
$5.5B
Jun 2026
$19.7B
Mar 2026
$17.3B
Dec 2025
$21.7B
Sep 2025
$23.0B
Jun 2025
$21.7B
Mar 2025
$18.8B
Dec 2024
$21.6B
Sep 2024
$14.2B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield RJF
FY Sep 2025
+6.5%
FY Sep 2024
+7.7%
FY Sep 2023
-17.6%
FY Sep 2022
-0.1%
FY Sep 2021
+51.9%
Jun 2026
+4.9%
Mar 2026
+8.4%
Dec 2025
+4.4%
Sep 2025
+6.5%
Jun 2025
+6.3%
Mar 2025
+6.9%
Dec 2024
+7.1%
Sep 2024
+7.7%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.10x
P/E over trailing EPS growth of 13%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing RJF
FY Sep 2025
2.76x
FY Sep 2024
0.58x
FY Sep 2023
0.91x
FY Sep 2022
2.60x
FY Sep 2021
0.20x
Jun 2026
1.06x
Mar 2026
7.10x
Dec 2025
n/a
Sep 2025
2.76x
Jun 2025
1.01x
Mar 2025
0.52x
Dec 2024
0.54x
Sep 2024
0.58x
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
RJF ranks highest on financial health (99th percentile) and institutional and government (89th), and lowest on insider conviction (14th), among Financial Services peers.
Profitability
69
Inputs
Return on equity+18.5% · 72 pct, sector of 205
Return on assets+2.6% · 65 pct, sector of 266
Return on invested capitalfewer than four consecutive quarters of operating income
Return on capital employedfewer than four consecutive quarters of operating income
Financial health
100
Inputs
Debt to equity0.00x · 100 pct, sector of 181
Cash flow to debtno debt to cover
Growth
41
Inputs
Revenue growth, YoY+6.6% · 41 pct, sector of 245
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
14
Inputs
Net Form 4 buying (codes P and S), 180d-$4.1M · 29 pct, sector of 160
Insider buyers, 180d0 · 0 pct, sector of 164
Institutional and government
89
Inputs
Funds adding, latest quarter407 · 89 pct, sector of 278
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
Short interest, % of float+3.6% · 49 pct, sector of 388
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+10.7% · 58 pct, sector of 175
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RJF filings, in plain words
Are Raymond James Financial insiders buying or selling RJF?
In the 180 days to 2026-10-28, Raymond James Financial insiders were net sellers, a net $4.1M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded RJF?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Julie Johnson dated 2025-04-07.
Are there planned insider sales of RJF?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $1.3M of stock; the latest, by Allaire Bella Loykhter, was filed 2026-08-28.
Read the full summary
In the 180 days to 2026-10-28, Raymond James Financial insiders were net sellers of RJF, a net $4.1M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in RJF, none in the last year; the latest on record is a sale by Julie Johnson dated 2025-04-07. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $1.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.